Research And Development
Shaping the future of noninvasive diagnostics with artificial intelligence.
Strong Scientific Expertise
Widely used, researched and validated patented test
Evaluating serum biomarkers LiverFast surrogates of liver fibrosis and steatosis could identify risks in a clinical population experiencing sars-cov2 infection (COVID).
Dr. Maryna Raskin
LIVERFASt™ & LIVERFASt Select
LIVERFASt™ Steatosis and Fibrosis scores are NITs that could be used to screen populations at risk of MetS and liver disease to identify those at risk of COVID-19.
Health Catalyst US
Dr. Brian Cohn
10,000 replicates per biomarker
Noise injection allows for nuanced tailoring & interpretation of results inferred by an AIA. We equip clinicians with an interactive tool to contextualize therapeutic expectations & aid in patient education towards adherence endpoints. In effect, providing a new, nuanced view of how AIA assess LD.
NAFL to advanced NASH n=2862
The modified SAF scoring system generated by LIVERFASt™ provided a simple & convenient diagnosis of NAFLD & NASH, and staging of the three liver lesions as shown in a cohort of SEA.
Prof. Lim Seng Gee
CHB n=724, LIVERFASt™
LF-Fibrosis & LF-Activity are reliable tools for screening HBV infected patients & for detecting phase-related liver disease, with better NPV than APRI or FIB-4. Management of HBV pts could be improved by LF tests.
National University Health System (NUHS) Singapore